Literature DB >> 26076697

Cancer Prevention Research in China.

Siwang Yu1, Chung S Yang2, Junyao Li3, Weicheng You4, Jianguo Chen5, Ya Cao6, Zigang Dong7, Youlin Qiao8.   

Abstract

Although cancer incidence and mortality rates in the United States and some European countries have started to decrease, those in developing countries are increasing. China, the most populous developing country, is facing a serious challenge from cancer. Cancer incidence has been increasing for decades, and cancer is the leading cause of death in China. In 2012, the cancer incidence was 174.0 per 100,000, and the cancer mortality was 122.2 per 100,000 in China. In addition to the still-prevalent traditional Chinese cancers of the stomach, liver, esophagus, cervix, and nasopharynx, the incidence of "Western" cancers such those of the lung, breast, and colorectum has increased alarmingly in recent years. These increases are likely due to the lifestyle and environmental changes associated with rapid economic development and population aging. More importantly, a large portion of these cancers are preventable. Researchers in China have made important contributions to cancer prevention research, especially in the traditional Chinese cancers. More cancer prevention research and measures, especially on the major emerging cancers, are urgently needed. This review article highlights some of the past achievements and present needs in cancer prevention research in China and suggests important areas for future studies. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26076697     DOI: 10.1158/1940-6207.CAPR-14-0469

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  11 in total

1.  CD90 positive cells exhibit aggressive radioresistance in esophageal squamous cell carcinoma.

Authors:  Yuandong Wang; Chi Zhang; Hongcheng Zhu; Junwei Tang; Shu Zhang; Jinhua Luo; Xinchen Sun
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer.

Authors:  Xiaochen Chen; Hao Zhang; Hongcheng Zhu; Xi Yang; Yuehua Yang; Yan Yang; Hua Min; Guangzong Chen; Jia Liu; Jing Lu; Hongyan Cheng; Xinchen Sun
Journal:  Tumour Biol       Date:  2015-10-28

3.  Exosomes Derived from Irradiated Esophageal Carcinoma-Infiltrating T Cells Promote Metastasis by Inducing the Epithelial-Mesenchymal Transition in Esophageal Cancer Cells.

Authors:  Hua Min; Xiangdong Sun; Xi Yang; Hongcheng Zhu; Jia Liu; Yuandong Wang; Guangzong Chen; Xinchen Sun
Journal:  Pathol Oncol Res       Date:  2017-01-28       Impact factor: 3.201

4.  Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease.

Authors:  Jing Li; Ni-Ya Ning; Qun-Xian Rao; Rong Chen; Li-Juan Wang; Zhong-Qiu Lin
Journal:  BMC Cancer       Date:  2017-08-03       Impact factor: 4.430

5.  EBV based cancer prevention and therapy in nasopharyngeal carcinoma.

Authors:  Ya Cao
Journal:  NPJ Precis Oncol       Date:  2017-05-15

6.  DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma.

Authors:  Xiangjian Luo; Liping Hong; Can Cheng; Namei Li; Xu Zhao; Feng Shi; Jikai Liu; Jia Fan; Jian Zhou; Ann M Bode; Ya Cao
Journal:  Cell Death Dis       Date:  2018-05-23       Impact factor: 8.469

7.  GJA1 Expression and Its Prognostic Value in Cervical Cancer.

Authors:  Silu Meng; Xinran Fan; Jianwei Zhang; Ran An; Shuang Li
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

8.  Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach.

Authors:  Jiekai Yu; Xiaohui Zhai; Xiaofen Li; Chenhan Zhong; Cheng Guo; Fuquan Yang; Ying Yuan; Shu Zheng
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

9.  miR-135a promotes gastric cancer progression and resistance to oxaliplatin.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Jia Chen; Wen-E Wei; Xian-Wei Mo; Yu-Zhou Qin; Yuan Lin; Jian-Si Chen
Journal:  Oncotarget       Date:  2016-10-25

10.  Patterns and changes in life expectancy in China, 1990-2016.

Authors:  Hai Chen; Yun Qian; Yunqiu Dong; Zhijie Yang; Liangliang Guo; Jia Liu; Qian Shen; Lu Wang
Journal:  PLoS One       Date:  2020-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.